Figure 1. Clinical Condition Rating at Nadir and Disease-Modifying Therapies in Patients With Multiple Sclerosis.

A, Patients were grouped according to coronavirus disease 2019 (COVID-19) severity score (from 1 [not hospitalized with no limitations on activities] to 7 [death]). B, Patients were grouped according to disease-modifying therapy. Systemic immunosuppression risk was adapted from Brownlee et al.³ Other treatments used by patients with multiple sclerosis included mycophenolate mofetil (n = 3), cyclophosphamide (n = 1), and methotrexate (n = 1).